



MINISTERIO
DE SANIDAD, CONSUMO
Y BIENESTAR SOCIAL



agencia española de
medicamentos y
productos sanitarios

DEPARTAMENTO DE
MEDICAMENTOS
VETERINARIOS

Agencia Española de Medicamentos y Productos Sanitarios

C/Campezo 1, Edificio 8
28022 – Madrid
España
(Reference Member State)

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

SEMELCEF 1000 mg tablets for dogs

CORREO ELECTRÓNICO

mresvet@aemps.es

temporalIP000851.docx

F-DMV-25-05

C/ CAMPEZO, 1 – EDIFICIO 8
28022 MADRID
TEL: 91 822 54 01
FAX: 91 822 5443

MODULE 1

PRODUCT SUMMARY

EU Procedure number	ES/V/0304/002/DC
Name, strength and pharmaceutical form	SEMELCEF 1000 mg tablets for dogs
Applicant	SUPPORT PHARMA, S.L. General Alvarez de Castro, 39 28010 Madrid, Spain
Active substance(s)	Cefadroxil
ATC Vet code	QJ01DB05
Target species	Dogs
Indication for use	Treatment of the following infections in dogs: <ul style="list-style-type: none">- Skin and soft tissue infections caused by <i>Staphylococcus</i> spp. and <i>Streptococcus</i> spp. (pyoderma, wounds, abscesses), susceptible to cefadroxil.- Urinary tract infections caused by <i>Staphylococcus</i> spp., <i>Streptococcus</i> spp., <i>Proteus mirabilis</i>, <i>Escherichia coli</i> and <i>Klebsiella</i> spp., susceptible to cefadroxil.- Upper respiratory tract infections caused by <i>Staphylococcus</i> spp., <i>Streptococcus</i> spp., and <i>Pasteurella multocida</i>, susceptible to cefadroxil.



MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies website (<http://www.hma.eu>).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Decentralised application in accordance with Article 13.1 of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	3 rd April, 2019
Date product first authorised in the Reference Member State (MRP only)	NA
Concerned Member States for original procedure	AT, BE, CY, CZ, EE, EL, HR, HU, IE, PL, PT, SI, SK,

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.



II. QUALITY ASPECTS

A. *Qualitative and quantitative particulars*

The product is presented as a square whitish tablet with two break-marks and contains cefadroxil monohydrate as the active substance and the excipients magnesium stearate and microcrystalline cellulose.

The container/closure system is PVC/PE/PVdC/PE/PVC blisters sealed with thermoheated aluminium foil packaged into a cardboard box.

The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation is justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. *Method of Preparation of the Product*

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. *Control of Starting Materials*

The active substance is cefadroxil monohydrate, an established substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Data relating to the active substance is presented in the form of a Ph. Eur. Certificate of Suitability (CEP).

D. *Control on intermediate products*

Not applicable.

E. *Control Tests on the Finished Product*



The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability

The Certificate of Suitability (CEP) of the active substance from the proposed source specifies the re-test period and storage conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

The in-use shelf-life of 3 days of the divided tablet after first use of the primary packaging is supported by the data provided.

G. Other Information

Not applicable.



III. SAFETY AND RESIDUES ASSESSMENT (PHARMACOTOXICOLOGICAL)

For generics, insert in the relevant sections as appropriate:

As this is a generic application according to Article 13 (1), and bioequivalence with a reference product has been demonstrated, results of safety tests are not required.

The safety aspects of this product is/are identical to the reference product.

Warnings and precautions as listed on the product literature are similar to those of the reference product and are adequate to ensure safety of the product to users and the environment.

III.A Safety Testing

Pharmacological Studies

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been demonstrated, results of pharmacological studies are not required.

Toxicological Studies

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been demonstrated, results of toxicological studies are not required.

The safety aspects of this product is identical to the reference product.

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline which shows that warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product:

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillin may lead to cross-reactions to cephalosporin and vice versa. Allergic reactions to these substances may occasionally be serious. Do not handle this veterinary medicinal product if you know you are sensitised or if you have been advised not to be in contact with such substances.

Handle this veterinary medicinal product with great care to avoid exposure, taking all recommended precautions. If you develop symptoms following exposure such as skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty breathing are more serious symptoms and require urgent medical attention.

Accidental ingestion may result in gastrointestinal disturbances. In order to reduce the risk of accidental ingestion by children, do not take the tablets out of the



blister until ready to administer to the animal. Return part-used tablets into the blister and carton and use at the subsequent administration.

In case of accidental ingestion, particularly by children, seek medical advice immediately and show the package leaflet or the label to the physician.

Do not smoke, eat or drink while handling the medication.

Wash hands after use.

Environmental Risk Assessment

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the veterinary medicinal product will only be used in non-food animals.

III.B Residues documentation

Not applicable



IV. CLINICAL ASSESSMENT (EFFICACY)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.



V . OVERALL CONCLUSION AND BENEFIT- RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website (www.hma.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

<None>

or

Complete this section for extensions to the same VPA range or defined, significant variations, using the table shown below.

Some examples of significant changes in safety or efficacy data are:

- *Changes to pharmacokinetic data leading to a change in the SPC*
- *Changes to toxicological data leading to a change in the SPC*
- *Changes to user safety warnings*
- *Changes to ecotoxicological information as given in the SPC or changes to disposal warnings*
- *New residue studies in new target species or tissues*
- *Reassessment of residue data or new studies resulting from changes to MRL*
- *Changes to withdrawal period*
- *Changes to target species*
- *Changes to target species tolerance data leading to change in warnings/precautions for target species*
- *New or changed indications*

Significant changes in administrative or quality data include any Type II change, which affects the initial report. The following Type IA or IB changes may also apply:

- *Name of product [Type IA: 2]*
- *Name of active substance [Type IA: 3]*
- *MAH [Type IA: 1]*
- *Composition of the medicinal product [Type IB: 18, Type IA/B: 25, 34, 35, 39]*
- *Container/closure system [Type 1/B: 26, 28, 29, 36, 41, 43]*
- *Method of preparation [Type 1B: 33]*
- *Active substance specification [Type IB: 25]*
- *CEP [Type IA/B: 15]*
- *Re-test period or storage conditions of active substance [Type IB: 17]*
- *Excipient specifications [Type 1A/B: 25]*
- *Packaging materials [Type 1A/B: 28, 29, 36, 41, 43]*
- *TSE [Type 1A: 16, 22]*



- *Shelf-life or storage conditions of the finished product [Type 1B: 42]*

Quality changes

Summary of change (Application number)	Section updated in Module 3	Approval date
<Example: Change to active substance specification> (MS/V/XXX/X/IB/XX)	N/A	

Safety/efficacy changes

Summary of change (Type; application number)	Section updated in Module 3	Approval date
<Example: Addition of target species - pigs> (MS/V/XXX/X/II/XX)	<IIIA> <IIIB> <IV>	